Wei‐Xing Guo
Impact in
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Hepatitis C virus research
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
- Hepatology 56
- Hepatocellular Carcinoma Treatment and Prognosis 56
- Co-authors
- Shuqun Cheng (55 shared papers)Jie Shi (50 shared papers)Jie Xue (21 shared papers)Mengchao Wu (23 shared papers)Wan Yee Lau (24 shared papers)Eric C. H. Lai (4 shared papers)Zhenhua Chen (22 shared papers)Xiuping Zhang (18 shared papers)
- Journals
- HPB (6 papers)Oncotarget (5 papers)Hepatology International (5 papers)Frontiers in Oncology (5 papers)BMC Cancer (4 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Wei‐Xing Guo
94 papers receiving 2.5k citations
Wei‐Xing Guo's Hit Papers
Peers
Comparison fields: 5 of 102
- Hepatology 1.4k
- Cancer Research 341
- Epidemiology 449
- Oncology 235
- Cell Biology 148
Countries citing papers authored by Wei‐Xing Guo
This map shows the geographic impact of Wei‐Xing Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Xing Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Xing Guo more than expected).
Fields of papers citing papers by Wei‐Xing Guo
This network shows the impact of papers produced by Wei‐Xing Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Xing Guo. The network helps show where Wei‐Xing Guo may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei‐Xing Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 227 | |
| 2 | 2013 | 226 | |
| 3 | 2010 | 144 | |
| 4 | 2011 | 131 | |
| 5 | 2018 | 98 | |
| 6 | 2015 | 85 | |
| 7 | 1999 | 82 | |
| 8 | 2013 | 78 | |
| 9 | 2009 | 78 | |
| 10 | Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial Hit paper breakdown → | 2024 | 77 |
| 11 | 2019 | 62 | |
| 12 | 2019 | 62 | |
| 13 | 2019 | 58 | |
| 14 | 2019 | 50 | |
| 15 | The CLN3 gene is a novel molecular target for cancer drug discovery. | 2002 | 45 |
| 16 | 2016 | 43 | |
| 17 | 2017 | 36 | |
| 18 | 2021 | 36 | |
| 19 | 1999 | 36 | |
| 20 | 2019 | 36 |
About Wei‐Xing Guo
Wei‐Xing Guo is a scholar working on Hepatology, Molecular Biology, Epidemiology, Oncology and Cancer Research, having authored 99 papers that have together received 2.5k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (56 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Liver Disease Diagnosis and Treatment (6 papers), Hepatitis B Virus Studies (4 papers), Cancer Mechanisms and Therapy (4 papers), Cancer, Hypoxia, and Metabolism (4 papers), Endoplasmic Reticulum Stress and Disease (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). The work is most often cited by research in Hepatology (1.4k citations), Cancer Research (341 citations), Epidemiology (449 citations), Oncology (235 citations) and Cell Biology (148 citations). Wei‐Xing Guo has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Shuqun Cheng, Jie Shi, Jie Xue, Mengchao Wu, Wan Yee Lau, Eric C. H. Lai, Zhenhua Chen, Xiuping Zhang, Kang Wang and Shuqun Cheng. Their work appears in journals such as HPB, Oncotarget, Hepatology International, Frontiers in Oncology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.